Discover
/
Article

Medical isotopes produced without nuclear reactor

JUN 11, 2013
Physics Today
Vancouver Sun : When the Canadian government shut down the Chalk River reactor in Ontario, it eliminated the source of 40% of the world’s technetium-99. The isotope is used in 90% of all nuclear medical imaging, including tracking blood flow and identifying tumors. Now, researchers at the British Columbia Cancer Agency have shown that they can make significant amounts of 99Tc using a particle accelerator known as a cyclotron . The accelerator, which collides atoms, has been known for more than 40 years to produce small amounts of various isotopes. Scientists on the $15 million program have been working to scale up the production rate since 2009. Most hospitals have secured supplies of necessary isotopes in the years since the Chalk River shutdown, but the new development may provide cheaper alternatives. However, because of the short half-life of 99Tc, a cyclotron can only supply nearby hospitals, so such facilities would likely only be established in larger urban areas.
Related content
/
Article
The finding that the Saturnian moon may host layers of icy slush instead of a global ocean could change how planetary scientists think about other icy moons as well.
/
Article
/
Article
After a foray into international health and social welfare, she returned to the physical sciences. She is currently at the Moore Foundation.
/
Article
Modeling the shapes of tree branches, neurons, and blood vessels is a thorny problem, but researchers have just discovered that much of the math has already been done.

Get PT in your inbox

pt_newsletter_card_blue.png
PT The Week in Physics

A collection of PT's content from the previous week delivered every Monday.

pt_newsletter_card_darkblue.png
PT New Issue Alert

Be notified about the new issue with links to highlights and the full TOC.

pt_newsletter_card_pink.png
PT Webinars & White Papers

The latest webinars, white papers and other informational resources.

By signing up you agree to allow AIP to send you email newsletters. You further agree to our privacy policy and terms of service.